Boostrix

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

InfluenzaPapillomaHerpes ZosterDiphtheria

1053 competitors in Influenza

#DrugCompanyPhaseTrials

1

Boostrix

GSK

Approved

12

Fluzone

Sanofi

Preclinical

163

Fluzone

GSK

Preclinical

374

Trexall

Alnylam Pharmaceuticals

Preclinical

15

Crestor

AstraZeneca

Preclinical

16

Avigan

AAppili Therapeutics Inc.

Preclinical

67

COMIRNATY

Pfizer

Preclinical

18

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

19

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

110

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14Show 9 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity19 trials

Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine

Completed·GSK·Phase 3·NCT00452686·660 enrolled

Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.

Completed·GSK·Phase 3·NCT00871000·303 enrolled

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

Completed·GSK·Phase 3·NCT00369824·1,330 enrolled

Show 16 more trials

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.

Completed·GSK·Phase 4·NCT00610168·82 enrolled

Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine

Completed·GSK·Phase 4·NCT00635128·415 enrolled

Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents

Completed·GSK·Phase 4·NCT01362322·671 enrolled

Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children

Completed·GSK·Phase 3·NCT01245049·387 enrolled

Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine

Completed·—·Phase 4·NCT00514059·83 enrolled

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058

Completed·GSK·Phase 4·NCT00548171·203 enrolled

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

Completed·GSK·Phase 2·NCT02360475·507 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

Completed·GSK·Phase 3·NCT01755689·1,300 enrolled

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

Completed·GSK·Phase 3·NCT00489970·1,954 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age

Completed·GSK·Phase 3·NCT01767376·692 enrolled

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults

Completed·GSK·Phase 3·NCT01738477·165 enrolled

Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.

Terminated·GSK·Phase 4·NCT00544271·720 enrolled

Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)

Completed·GSK·Phase 4·NCT01294605·460 enrolled

Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects

Completed·GSK·Phase 3·NCT03311659·448 enrolled

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

Completed·GSK·Phase 3·NCT00346073·2,337 enrolled

A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

Recruiting·GGC Biopharma Corp·Phase 1/2·NCT06997627·120 enrolled

Vaccine4 trials

Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine

Completed·GSK··NCT00297856·10,000 enrolled

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

Completed·GSK·Phase 3·NCT00835237·1,332 enrolled

Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.

Completed·GSK·Phase 3·NCT00406562·30 enrolled

Show 1 more trial

Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea

Completed·GSK··NCT01929291·682 enrolled

Immune Response3 trials

A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults

Completed·GSK·Phase 2·NCT02676895·74 enrolled

Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune Responses

Completed·UUniversity Hospital, Ghent·Phase 4·NCT02555540·240 enrolled

A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

Completed·Eli Lilly·Phase 1·NCT02543918·84 enrolled

Diphtheria2 trials

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

Completed·GSK·Phase 4·NCT00282295·1,344 enrolled

Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®

Completed·GSK·Phase 3·NCT01277705·806 enrolled

Pregnancy1 trial

Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand

Completed·UUniversiteit Antwerpen·Phase 4·NCT02408926·370 enrolled

10 more indications

Papilloma1 trial

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

Completed·GSK·Phase 3·NCT00426361·751 enrolled

Influenza1 trial

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

Completed·GSK·Phase 3·NCT00385255·1,726 enrolled

Respiratory Syncytial Virus (RSV)1 trial

Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women

Completed·GSK·Phase 2·NCT02753413·102 enrolled

Herpes Zoster1 trial

Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older

Completed·GSK·Phase 3·NCT02052596·935 enrolled

Pertussis1 trial

Viaskin Pertussis Vaccine Trial

Completed·DDBV Technologies·Phase 1·NCT03035370·102 enrolled

Trial1 trial

The PertADO Geneva Trial

Completed·SSiegrist Claire-Anne·Phase 2·NCT02946190·60 enrolled

Pregnant Women1 trial

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women

Completed·GSK·Phase 4·NCT02377349·688 enrolled

Children1 trial

Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children

Completed·GSK·Phase 3·NCT01988857·302 enrolled

Vaccination1 trial

Evaluation of Boostrix™10 Years After Previous Booster Vaccination

Completed·GSK·Phase 4·NCT01147900·180 enrolled

Adult1 trial

A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays

Completed·GSK·Phase 4·NCT02072525·359 enrolled

Details

Drug Info

Related News